Vaxart, Immunovaccine, Mayo Clinic jump onto Zika vaccine bandwagon
Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.
U.K. rejects petition demanding meningitis B vaccine for all children
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine. Read more >>
Philippines' immunization program for Sanofi's Dengvaxia set to start in April
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine. Read more >>
TOP HEADLINES
Featured Story
Sanofi digs into details on hastened Zika effort
Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.
Valneva scores $42M supply contract with DOD
Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.
Health agencies inform on Zika vaccine timeline
Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.
Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market
Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.
Journal walks back 'seriously flawed' study critical of Merck's Gardasil
Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.
Duke, NIAID track HIV evolution with eyes on creating a vaccine
A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
From Our Sister Sites
- FierceBiotech
- FierceBiotechIT
- FierceBiotechResearch
- FierceDrugDelivery
- FierceMedicalDevices
- FierceVaccines
- FiercePharma
- FiercePharmaAsia
- FiercePharmaManufacturing
- FierceCRO
- FierceDiagnostics
- FiercePharmaMarketing
- FierceAnimalHealth
- More Fierce Network sites
Super-resolution microscopy tech was used to track the tipping point in Parkinson's disease; the change in chemistry in the brain that triggers the disease.
Kinase inhibitors follow a well-known pathway in fighting back cancer. But a researcher team at MIT says they've identified a previously "unappreciated" backup mechanism that can be triggered when the inhibitors hit that allows the cancer to progress. And they've identified a combination approach in a preclinical study that may allow for a more durable effect.
POPULAR COMMENT THREADS